3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Melanoma
2
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Leukemia
1
Healthy Participants
1
Endometrial Neoplasms
1
Disease Progression
1
Chondrosarcoma
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Interventions
pembrolizumab
49
Specimen Handling
29
Magnetic Resonance Spectroscopy
25
Biopsy
25
Radiosurgery
17
Gemcitabine
17
Nivolumab
16
Cyclophosphamide
14
Cisplatin
14
Paclitaxel
13
Carboplatin
13
Bevacizumab
13
Leucovorin
11
Irinotecan
11
Fluorouracil
11
Drug Therapy
11
Taxes
10
Radiotherapy
10
Oxaliplatin
10
Capecitabine
10
trastuzumab deruxtecan
9
fludarabine
9
cemiplimab
8
Doxorubicin
8
Cetuximab
8
abemaciclib
7
Trastuzumab
7
Pemetrexed
7
Fulvestrant
7
Docetaxel
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm Metastasis
×
capivasertib
×
Clear all
NCT07281833
2026-02-27
CAPIcorn
West German Study Group
Phase 3
Recruiting
250 enrolled